An Unorthodox Path to Medical Device Success
Innovation is second nature to Joe Landolina. As someone who grew up in an environment that fostered curiosity and learning, with a grandfather who ran a chemistry lab, it’s no surprise that Joe invented the technology of Cresilon’s flagship product Vetigel at the youthful age of 17.
This biotech just raised $25M to develop plant-based gel that stops traumatic bleeding in seconds
InnovationRx: Healthcare’s 2023 Outlook, Covid Hospitalizations Are Rising And What To Know About RSV
Interview: 17-year-old invents life-saving gel technology
When he was 17 years old, Joe Landolina created a revolutionary gel. Now, he is 29 years old and co-founder and CEO of Cresilon, his homegrown Brooklyn-based biotech company that recently submitted the gel for FDA 510(k) clearance for human use and raised $38.5 million in Series A3 financing last year. DDW’s Megan Thomas caught up with Landolina about his success story.
How This Plant-Based Gel Can Treat Wounds
Cresilon Announces Distribution Agreement for VETIGEL with Penn Veterinary Supply
NEW YORK (August 22, 2023) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.
Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology
June 29, 2023, New York – Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for Cresilon Hemostatic Gel™ (“CHG™”).
Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market
Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries
“Cresilon is extremely proud and honored to be supporting the DoD and WRAIR in this critically important work,” said Joe Landolina, CEO of Cresilon. “This collaboration is a testament to the potential of our technology, and we are truly hopeful that it can make a difference in the treatment of TBI and in the precious lives of our soldiers.”
Subscribe to our Newsletter
Stay in touch with us to get Cresilon’s news, investment opportunities, and product releases.